glp-1 drugs mechanism of action GLP1-GIP receptor co-agonists: a promising evolution in the treatment type 2 diabetes | Acta Diabetologica GLP-1 Receptor Agonists as Treatments

Entero-endocrine-osseous axis : gastrointestinal hormones as substrates for DPP-4 The initial observation that patients receiving long-term parenteral nutrition develop osteoporosis and osteomalacia raised suspicion about the lack of stimulation for the secretion of incretin hormones in this mode of nutrition and a potential connection between these hormones and bone metabolism [42]

Front Endocrinol (Lausanne) 2022;13:923606

V., Shakhmatoba, E

References 1.World Heath Organization

Regional Insights North America continues to be the largest market for GLP-1 receptor agonists, owing to the region's high incidence of diabetes and obesity, which are key risk factors for the diseases these drugs target

That could make GLP-1 drugs more affordable and easier to access for many Canadians